"Designing Growth Strategies is in our DNA"

U.S. Vaginal Atrophy Treatment Market Size, Share & Industry Analysis, By Therapy Type (Drug Therapies {Estrogen Based [Imvexxy, Premarin, and Others], Non-Estrogen Based [Intrarosa, Osphena, and Others]}, and Non-Drug Therapies {Light Therapy, Laser, and Others}), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Store & Pharmacies, and Online Channels), and Country Forecast, 2025-2032

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109727

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2023

Estimated Year

2024

Forecast Period

2024-2032

Historical Period

2019-2023

Growth Rate

CAGR of 4.1% from 2025-2032

Unit

Value (USD Billion)

Segmentation

By Therapy Type

  • Drug Therapies
    • Estrogen Based
      • Imvexxy
      • Premarin
      • Others
    • Non-Estrogen Based
      • Intrarosa
      • Osphena
      • Others
  • Non-Drug Therapies
    • Light Therapy
    • Laser
    • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Stores & Pharmacies
  • Online Channels
  • 2019-2032
  • 2024
  • 2019-2023
  • 88
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann